Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Closely followed investor Stanley Druckenmiller increased exposure to some big technology companies in the final quarter of ...

Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both ...

New York, New York-- (Newsfile Corp. - February 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

New York, New York-- (Newsfile Corp. - February 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

The FDA has approved Eli Lilly’s Emgality (galcanezumab ... unapproved therapies such as Botox and anti-seizure medication. Teva’s CGRP drug Ajovy (fremanezumab) was approved by the FDA ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab ... Tanezumab and Regeneron/Teva’s fasinumab are the last survivors in a class ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...